# Ventrix Bio

> Ventrix Bio is a San Diego biotechnology company developing cell-free extracellular-matrix biotherapeutics that aim to help damaged tissue repair itself. Its first program, VentriGel, turns decellularized porcine cardiac matrix into a liquid that can be injected through a catheter and gels at body temperature. After a completed 15-patient Phase 1 safety and feasibility study, Ventrix shifted toward an infusible ECM formulation designed for delivery during an acute heart attack; the company remains pre-commercial and its clinical benefit has not yet been established in a randomized trial.

- **Founded:** 2009
- **Headquarters:** San Diego, United States
- **Founders:** Adam Kinsey (Co-founder and Chief Executive Officer), Karen L. Christman (Scientific Co-founder)
- **Team size:** 16 employees reported in the supplied company data; LinkedIn publicly describes the company as 2-10 employees, so the current operating headcount is uncertain.
- **Products:** VentriGel, Infusible ECM (iECM)
- **Notable:** Licensed cardiac ECM hydrogel technology from UC San Diego and built a patent portfolio around catheter-deliverable cardiac therapy., Advanced VentriGel from rodent and porcine models to an FDA-cleared IND and first-in-human Phase 1 study., Completed a six-site, 15-patient Phase 1 trial with all participants completing six-month follow-up.

## Products & services

- **VentriGel** — An investigational, catheter-deliverable hydrogel made from decellularized porcine myocardial extracellular matrix for patients with left-ventricular dysfunction after myocardial infarction. It completed a 15-patient Phase 1 safety and feasibility study but is not approved or commercially available.
- **Infusible ECM (iECM)** — A preclinical soluble ECM formulation designed for intracoronary infusion immediately after acute myocardial infarction, avoiding the multiple transendocardial injections required by VentriGel.

## Achievements

- Licensed cardiac ECM hydrogel technology from UC San Diego and built a patent portfolio around catheter-deliverable cardiac therapy.
- Advanced VentriGel from rodent and porcine models to an FDA-cleared IND and first-in-human Phase 1 study.
- Completed a six-site, 15-patient Phase 1 trial with all participants completing six-month follow-up.
- Published first-in-human results in JACC: Basic to Translational Science in 2019, supporting safety and feasibility while calling for a larger randomized trial.
- Secured six SBIR awards totaling $6,546,768 according to the federal SBIR portfolio database.
- Developed an infusible ECM formulation intended for intracoronary delivery during acute myocardial infarction.

## Latest updates

- **2026-07** — The NIH project record lists July 31, 2026 as the scheduled end of Ventrix's current Phase II SBIR project for pivotal preclinical studies of infusible ECM; public records do not establish a clinical start.
- **2024-09** — NIH recorded $1,440,231 in fiscal-year 2024 funding for Ventrix's ongoing infusible ECM project.
- **2023-09** — A $1,992,340 NHLBI Phase II SBIR project began to support pivotal preclinical studies of infusible ECM for acute myocardial infarction.
- **2020-09** — Ventrix began a $791,543 Phase I SBIR program to optimize a soluble version of its ECM hydrogel for intracoronary infusion.
- **2019-09** — Ventrix and academic collaborators published the completed 15-patient Phase 1 VentriGel study, reporting safety and feasibility and recommending larger randomized evaluation.

## Links

- Website: https://ventrixbio.com
- LinkedIn: https://www.linkedin.com/company/ventrix/
- Twitter/X: https://twitter.com/ventrixheart
- Facebook: https://facebook.com/ventrixheart

---

Profile page: https://yespress.io/ventrix
Published by YesPress — https://yespress.io
Last updated: 2026-08-20